Company Focus
Vertex Pharmaceuticals
Latest Vertex Pharmaceuticals News
Pharmaceutical
US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s presentation of its third-quarter financial results and latest outlook for 2024 as a whole. 5 November 2024
Related News
Insights
Company Spotlight
A clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with diseases of the eye, salivary gland and central nervous system.
Latest News & Features of interest to Vertex Pharmaceuticals
Biotechnology
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Biotechnology
Biogen revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, has received Breakthrough Therapy designation. 9 October 2024
Biotechnology
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
Biotechnology
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Iqirvo (elafibranor), from French drugmaker Ipsen. 8 October 2024
Biotechnology
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906). 8 October 2024
Pharmaceutical
Japanese drugmaker Eisai has received approval in Thailand for Urece (dotinurad), a treatment for gout and hyperuricemia. 8 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Generics
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
Latest In Brief for Vertex Pharmaceuticals
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Latest Relevant Ones To Watch News
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
29 October 2024
24 September 2024
19 September 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze